

NCIC CLINICAL TRIALS GROUP

**ADVANCED PROSTATE**

GU DISEASE ORIENTED GROUP MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON  
ROOM: WREN  
SATURDAY MAY 2<sup>ND</sup>, 2015, 8:00 AM – 9:00 AM

CO-CHAIRS: K. CHI & F. SAAD  
SENIOR INVESTIGATOR: WENDY PARULEKAR  
STUDY COORDINATOR: ALEXANDER MONTENEGRO

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- To understand and address, through clinical and translational research, the disease burden associated with advanced prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to advanced prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to advanced prostate cancer.

---

<b>8:00 am</b>	<b>Welcome, Objectives, Agenda</b>	<b>K. Chi</b>
<b>8:05 am</b>	<b>Trials With Issues</b>	
	<b>PRC.4:</b> Alliance Phase III Enzalutamide +/- Abiraterone in CRPC	<b>K. Chi</b>
<b>8:15 am</b>	<b>New Trial Proposals</b>	
	<b>CTC-STOP:</b> Utilizing Circulating Tumor Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.	<b>J. de Bono</b>
	<b>TOPARP:</b> A phase II double-blind placebo controlled trial of olaparib 400mg BID vs placebo in unselected patients with advanced castration resistant prostate cancer who have not received taxane-based chemotherapy.	<b>J. de Bono</b>
	<b>ADT-MeMS:</b> The Androgen Deprivation Therapy Metformin Metabolic Syndrome Trial	<b>B. Eigl</b>
<b>9:00 am</b>	<b>Meeting adjourned</b>	